Back to Search
Start Over
Acute respiratory distress syndrome after rituximab infusion.
- Source :
-
International journal of hematology [Int J Hematol] 2005 Nov; Vol. 82 (4), pp. 324-6. - Publication Year :
- 2005
-
Abstract
- Rituximab, a humanized monoclonal antibody approved for malignant lymphoma, is being increasingly, effectively, and safely used for immune thrombocytopenic purpura (ITP) and other humoral autoimmune disorders. We report the case of a 43-year-old man with ITP refractory to steroids and intravenous immunoglobulin who developed acute respiratory distress syndrome (ARDS) after a single infusion of rituximab. Dyspnea, hypoxemia, and pleuritic chest pain occurred within 24 hours of rituximab administration, and there was no other apparent explanation. Progressive hypoxemia mandated endotracheal intubation 1 week after rituximab administration and led to death 4 weeks after admission. ARDS has been associated with the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines. ARDS is rarely associated with rituximab infusion for lympho-proliferative disorders, but it should be considered by those administering rituximab, especially when a patient develops severe pulmonary symptoms soon after infusion.
- Subjects :
- Adult
Antibodies, Monoclonal, Murine-Derived
Fatal Outcome
Humans
Male
Radiography, Thoracic
Respiratory Distress Syndrome diagnostic imaging
Rituximab
Tomography, X-Ray Computed
Antibodies, Monoclonal adverse effects
Antineoplastic Agents adverse effects
Lymphoma drug therapy
Respiratory Distress Syndrome chemically induced
Subjects
Details
- Language :
- English
- ISSN :
- 0925-5710
- Volume :
- 82
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- International journal of hematology
- Publication Type :
- Academic Journal
- Accession number :
- 16298824
- Full Text :
- https://doi.org/10.1532/IJH97.NA0506